OptiBiotix Health PLC Launch of SlimBiome® in North America
January 31 2020 - 2:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
31 January 2020
31 January 2020
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Launch of SlimBiome(R) in North America with Agropur Inc.
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, and Agropur Inc. ("Agropur") have announced the
launch of SlimBiome in the North American market. This launch
follows the announcement (RNS: 24 June 2019) that OptiBiotix
granted Agropur an exclusive license to manufacture, supply and
distribute OptiBiotix's SlimBiome(R) weight management technology
in the USA, Canada and Mexico.
Agropur is a wholly owned subsidiary of Agropur Cooperative,
which is a North American dairy industry leader founded in 1938.
With 8,800 employees and sales of US$5.5 billion in 2019, Agropur
processes more than 14 billion lbs of milk per year at its 38
plants across North America.
Mike Homewood, Vice President of Agropur Custom Solutions, said,
"We are proud of our agreement and partnership with OptiBiotix and
the exclusive opportunity to bring SlimBiome(R) to the North
American food and nutrition industries. This ingredient solution
for weight management fits into Agropur's goal to provide
innovative, forward-thinking products to our customers."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division, commented, "We are very pleased with the progress Agropur
has made since the announcement of our partnership at the end of
June 2019. Over a rather short period of time, Agropur has
qualified its manufacturing process and is now able to produce
SlimBiome(R) in the USA and supply the ingredient to North American
B2B customers. This is a key strategic step In OptiBiotix's
commercial development as it grants the company access to the US
weight management market which was estimated to be worth US$72
billion in 2019 (source: BusinessWire.com)."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 20 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFLFVELRIIVII
(END) Dow Jones Newswires
January 31, 2020 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
